Department of Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453002, China.
Schizophr Res. 2013 Mar;144(1-3):129-35. doi: 10.1016/j.schres.2012.12.021. Epub 2013 Jan 24.
Olanzapine is an atypical antipsychotic for the treatment of schizophrenia, in which memory impairment is a core deficit. The methods of positive and negative syndrome scale (PANSS), Wechsler memory scale-4th edition (WMS-IV) and event-related potential (ERP) were used to study the effects of olanzapine on the cognitive function in the first-episode schizophrenic patients. We performed multicentre, randomized, double-blind, placebo-controlled, parallel-group clinical trial to study the cognitive functioning in Han Chinese first-episode schizophrenic patients in a 12-week treatment regime with olanzapine (129 cases) or placebo (132 cases). The results showed that (1) the patients with first-episode schizophrenia showed significant deficits in the long-term memory, short-term memory, immediate memory and memory quotient by WMS-IV assessment, and decreases the total scores, positive symptoms, negative symptoms and general psychopathology by PANSS assessment; (2) olanzapine could significantly improve the PANSS scores including total scores, positive symptoms, negative symptoms and general psychopathology in the first-episode schizophrenic patients; (3) olanzapine could significantly improve the short-term memory, immediate memory and memory quotient in the first-episode schizophrenic patients; and (3) although the latencies of P(2), N(2) and P(3) were significantly prolonged, P(2) and P(3) amplitudes were decreased and the latencies of N(1) did not change, olanzapine did not influence any P(300) items in the first-episode schizophrenic patients. The data suggested that that olanzapine could improve cognitive process, such as memorizing and extraction of the information although there were many changes of cognitive functions in Han Chinese first-episode schizophrenic patients.
奥氮平是一种用于治疗精神分裂症的非典型抗精神病药物，而记忆损伤是其核心缺陷之一。本研究采用阳性和阴性症状量表（PANSS）、韦氏记忆量表第四版（WMS-IV）和事件相关电位（ERP）的方法，观察奥氮平对首发精神分裂症患者认知功能的影响。采用多中心、随机、双盲、安慰剂对照、平行分组临床试验，以奥氮平（129 例）或安慰剂（132 例）治疗 12 周，观察奥氮平对汉族首发精神分裂症患者认知功能的影响。结果表明：（1）首发精神分裂症患者 WMS-IV 测试长时记忆、短时记忆、即刻记忆和记忆商明显受损，PANSS 测试总分、阳性症状、阴性症状和一般精神病理评分降低；（2）奥氮平可显著改善首发精神分裂症患者的 PANSS 总分、阳性症状、阴性症状和一般精神病理评分；（3）奥氮平可显著改善首发精神分裂症患者的短时记忆、即刻记忆和记忆商；（4）奥氮平对首发精神分裂症患者 P300 各指标均无影响，虽然潜伏期 P（2）、N（2）和 P（3）明显延长，P（2）和 P（3）波幅降低，N（1）潜伏期无变化。结果提示，奥氮平可能改善了认知过程，如信息的记忆和提取，尽管汉族首发精神分裂症患者的认知功能发生了许多变化。
